Takeda to Acquire GammaDelta to Advance the Development of Allogeneic ?dT Cell Therapies for the Treatment of Solid Tumors
Shots:
- Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close in Q1'22
- The acquisition follows a 2017 collaboration b/w Takeda & GammaDelta to develop GammaDelta's novel d T cell therapy platforms. Takeda will obtain GammaDelta's allogeneic Vd1 gamma-delta (d) T cell therapy platforms including both blood-derived and tissue-derived platforms in addition to early-stage cell therapy programs
- The acquisition will bolster Takeda's immuno-oncology and innate immune cell therapy portfolio with the addition of d T cell therapy platforms for solid tumors & hematological malignancies
to | Ref: Takeda | Image: Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com